Eledon Pharmaceuticals
ELDN
32 hedge funds and large institutions have $27.6M invested in Eledon Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 6 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
6.15% less ownership
Funds ownership: 55.1% → 48.95% (-6.1%)
11% less funds holding
Funds holding: 36 → 32 (-4)
21% less capital invested
Capital invested by funds: $34.7M → $27.6M (-$7.15M)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $69K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$3.68M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$483K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
+$426K |
| 4 |
B
Bailard
Foster City,
California
|
+$107K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$69.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.91M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.22M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$420K |
| 4 |
Two Sigma Investments
New York
|
-$220K |
| 5 |
Two Sigma Advisers
New York
|
-$169K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Simplex Trading
Chicago,
Illinois
| $6K | -$4.05K | -1,046 | -38% |
|
27
Rockefeller Capital Management
New York
| $6K | – | – | – |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| $5K | -$2.83K | -730 | -36% |
|
|
SWM
29
Spire Wealth Management
Mclean,
Virginia
| $3K | – | – | – |
|
30
Federated Hermes
Pittsburgh,
Pennsylvania
| $2K | +$1.52K | +392 | +186% |
|
|
IA
31
IFP Advisors
Tampa,
Florida
| $1K | +$4 | +1 | New |
|
|
LGM
32
Logos Global Management
San Francisco,
California
| – | -$5.91M | -1,339,793 | Closed |
|
|
33
Fidelity Investments
Boston,
Massachusetts
| – | -$2.22M | -504,371 | Closed |
|
|
AAS
34
Ameritas Advisory Services
Lincoln,
Nebraska
| – | -$107K | -24,219 | Closed |
|
35
Citadel Advisors
Miami,
Florida
| – | -$39.4K | -10,174 | Closed |
|
36
UBS Group
Zurich,
Switzerland
| – | -$16K | -3,638 | Closed |
|
ELDN Hedge Fund Activity: Q1 2022 in Review
32 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q1 2022, worth a combined $27.6M — down 21% from $34.7M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ELDN and 2 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 8 added.
The largest buyer was BVF Inc, adding an estimated $3.68M. The largest seller was Logos Global Management, exiting entirely with an estimated $5.91M sold.
- 32 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q1 2022, down from 36 in Q4 2021.
- Funds reported $27.6M of Eledon Pharmaceuticals stock for Q1 2022, down 21% quarter-over-quarter.
- 2 funds opened new Eledon Pharmaceuticals positions in Q1 2022 and 6 closed out, a net change of -4 holders.
- The largest Eledon Pharmaceuticals buyer in Q1 2022 was BVF Inc, an estimated $3.68M added.
- The largest Eledon Pharmaceuticals seller in Q1 2022 was Logos Global Management, an estimated $5.91M sold.
Based on aggregated 13F filings for Q1 2022.